-
| Industry | Medical Devices |
|---|---|
| Sector | Healthcare |
| ISIN | US54948X1090 |
| CurrencyCode | USD |
| Exchange | NASDAQ |
| PE Ratio | None |
|---|---|
| Market Cap | 66M |
| Dividend Yield | 0.0% |
| Target Price | 7.65 |
| Beta | nan |
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for LUCD using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024